Stocks Comparison
Agilent Technologies vs Bio-Rad Laboratories: revenue, profit, margins and growth compared
Agilent Technologies brought in $6.9B of revenue in fiscal 2025, Bio-Rad Laboratories $2.6B in fiscal 2025. Revenue changed by +6.7% at Agilent Technologies and +0.7% at Bio-Rad Laboratories on the year before, so Agilent Technologies grew faster. Agilent Technologies kept 18.8% of its revenue as net profit, Bio-Rad Laboratories 29.4%. Free cash flow was $1.2B at Agilent Technologies and $374.6M at Bio-Rad Laboratories.
Side by side, latest fiscal year
| A | BIO | |
|---|---|---|
| Fiscal year ended | FY2025 (October 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $6.9B | $2.6B |
| Revenue growth | +6.7% | +0.7% |
| Net income | $1.3B | $759.9M |
| Net margin | 18.8% | 29.4% |
| Free cash flow | $1.2B | $374.6M |
| Free cash flow margin | 16.6% | 14.5% |
| Earnings per share (diluted) | $4.57 | $27.85 |
| Cash | $1.8B | $529.8M |
| Debt | $3.1B | $1.2B |
| Price to earnings | 37.8 | 13.7 |
| Market value | $48.8B | $10.2B |
| Dividend yield | 0.57% | n/a |
| Rank by revenue in sector | #97 of 451 · Industrials | #194 of 451 · Industrials |
Over the years
Questions about Agilent Technologies and Bio-Rad Laboratories
Which is bigger by revenue, Agilent Technologies or Bio-Rad Laboratories?
Agilent Technologies is bigger by revenue: $6.9B in fiscal 2025, against $2.6B for Bio-Rad Laboratories in fiscal 2025.
Which keeps more of its revenue as profit, Agilent Technologies or Bio-Rad Laboratories?
Agilent Technologies had a net margin of 18.8% in fiscal 2025; Bio-Rad Laboratories had 29.4% in fiscal 2025.
Which grew revenue faster, Agilent Technologies or Bio-Rad Laboratories?
In their latest fiscal years revenue changed by +6.7% at Agilent Technologies and +0.7% at Bio-Rad Laboratories.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.